Combinatorial effect of probucol and cilostazol in focal ischemic mice with hypercholesterolemia

Journal of Pharmacology and Experimental Therapeutics

Volumn 338, Issue 2, 2011, Pages 451-457

  Kim, Ji Hyun ^a   Park, Sun Haeng ^a   Bae, Sun Sik ^b   Hong, Ki Whan ^b   Kim, Yong Deok ^a   Park, Kyung Pil ^c   Choi, Byung Tae ^a   Shin, Hwa Kyoung ^a  

^a Pusan National University   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

^c Pusan National University Yangsan Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN E; CILOSTAZOL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; PROBUCOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROSIS; BRAIN BLOOD FLOW; BRAIN CORTEX; BRAIN INFARCTION; BRAIN ISCHEMIA; CONTROLLED STUDY; GENE SILENCING; HYPERCHOLESTEROLEMIA; LIPID DIET; LIPOPROTEIN BLOOD LEVEL; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; UPREGULATION; VASCULAR ENDOTHELIUM;

ANIMALS; BRAIN ISCHEMIA; CEREBROVASCULAR CIRCULATION; DRUG THERAPY, COMBINATION; HYPERCHOLESTEROLEMIA; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROBUCOL; TETRAZOLES;

EID: 79960516617     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.181180     Document Type: Article

References (40)

1. Amarenco P (2001) Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction. Neurology 57:S35-S44.
2. Amarenco P and Labreuche J (2009) Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 8:453-463.
3. Casino PR, Kilcoyne CM, Quyyumi AA, Hoeg JM, and Panza JA (1993) The role of nitric oxide in endothelium-dependent vasodilation of hypercholesterolemic patients. Circulation 88:2541-2547. (Pubitemid 23360178)
4. Chen MP, Tsai JC, Chung FM, Yang SS, Hsing LL, Shin SJ, and Lee YJ (2005) Hypoadiponectinemia is associated with ischemic cerebrovascular disease. Arterioscler Thromb Vasc Biol 25:821-826. (Pubitemid 40463876)
5. Choi JM, Shin HK, Kim KY, Lee JH, and Hong KW (2002) Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats. J Pharmacol Exp Ther 300:787-793. (Pubitemid 34164980)
6. Collins R, Armitage J, Parish S, Sleigh P, Peto R, and Heart Protection Study Collaborative Group (2003) MRC/BHF Heart Protection Study of cholesterollowering with simvastatin in 5963 people with diabetes: a randomised placebocontrolled trial. Lancet 361:2005-2016.
7. da Rosa MP, Baroni GV, and Portal VL (2006) Cilostazol, a phosphodiesterase III inhibitor: future perspectives in atherosclerosis. Arq Bras Cardiol 87:e222-e226.
8. d'Uscio LV, Smith LA, and Katusic ZS (2001) Hypercholesterolemia impairs endothelium-dependent relaxations in common carotid arteries of apolipoprotein e-deficient mice. Stroke 32:2658-2664.
9. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, and Liao JK (1998) Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 95:8880-8885. (Pubitemid 28350583)
10. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, Culebras A, Degraba TJ, Gorelick PB, Guyton JR, et al. (2006) Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke 37:1583-1633. (Pubitemid 44313592)
11. Hashimoto A, Miyakoda G, Hirose Y, and Mori T (2006) Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosclerosis 189:350-357. (Pubitemid 44634499)
12. Hsieh CJ and Wang PW (2009) Effect of cilostazol treatment on adiponectin and soluble CD40 ligand levels in diabetic patients with peripheral arterial occlusion disease. Circ J 73:948-954.
13. Huang Z, Huang PL, Panahian N, Dalkara T, Fishman MC, and Moskowitz MA (1994) Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science 265:1883-1885. (Pubitemid 24324247)
14. Ishikawa M, Stokes KY, Zhang JH, Nanda A, and Granger DN (2004) Cerebral microvascular responses to hypercholesterolemia: roles of NADPH oxidase and P-selectin. Circ Res 94:239-244. (Pubitemid 38197457)
15. Jürgens G, Taddei-Peters WC, Költringer P, Petek W, Chen Q, Greilberger J, Macomber PF, Butman BT, Stead AG, and Ransom JH (1995) Lipoprotein(a) serum concentration and apolipoprotein(a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. Stroke 26:1841-1848.
16. Kuzuya M and Kuzuya F (1993) Probucol as an antioxidant and antiatherogenic drug. Free Radic Biol Med 14:67-77. (Pubitemid 23024259)
17. Lau AK, Leichtweis SB, Hume P, Mashima R, Hou JY, Chaufour X, Wilkinson B, Hunt NH, Celermajer DS, and Stocker R (2003) Probucol promotes functional reendothelialization in balloon-injured rabbit aortas. Circulation 107:2031-2036. (Pubitemid 36506079)
18. Lee JH, Oh GT, Park SY, Choi JH, Park JG, Kim CD, Lee WS, Rhim BY, Shin YW, and Hong KW (2005) Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol. J Pharmacol Exp Ther 313:502-509. (Pubitemid 40604148)
19. Lee JH, Park SY, Shin HK, Kim CD, Lee WS, and Hong KW (2007) Poly(ADP-ribose) polymerase inhibition by cilostazol is implicated in the neuroprotective effect against focal cerebral ischemic infarct in rat. Brain Res 1152:182-190. (Pubitemid 46802504)
20. Li X, Blizzard KK, Zeng Z, DeVries AC, Hurn PD, and McCullough LD (2004) Chronic behavioral testing after focal ischemia in the mouse: functional recovery and the effects of gender. Exp Neurol 187:94-104. (Pubitemid 38470016)
21. Matsuda M, Shimomura I, Sata M, Arita Y, Nishida M, Maeda N, Kumada M, Okamoto Y, Nagaretani H, Nishizawa H, et al. (2002) Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 277:37487-37491.
22. Mogi M, Iwai M, Chen R, Iwanami J, Ide A, Tsukuda K, Yoshii T, and Horiuchi M (2006) Amlodipine treatment reduces stroke size in apolipoprotein E-deficient mice. Am J Hypertens 19:1144-1149. (Pubitemid 44633592)
23. Nakamura T, Houchi H, Minami A, Sakamoto S, Tsuchiya K, Niwa Y, Minakuchi K, and Nakaya Y (2001) Endothelium-dependent relaxation by cilostazol, a phosphodiesteras III inhibitor, on rat thoracic aorta. Life Sci 69:1709-1715. (Pubitemid 32785280)
24. Nishimura M, Izumiya Y, Higuchi A, Shibata R, Qiu J, Kudo C, Shin HK, Moskowitz MA, and Ouchi N (2008) Adiponectin prevents cerebral ischemic injury through endothelial nitric oxide synthase dependent mechanisms. Circulation 117:216-223.
25. Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, and Walsh K (2003) Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 14:561-566. (Pubitemid 41623184)
26. Park SY, Lee JH, Kim CD, Rhim BY, Hong KW, and Lee WS (2007) Beneficial synergistic effects of concurrent treatment with cilostazol and probucol against focal cerebral ischemic injury in rats. Brain Res 1157:112-120. (Pubitemid 46935073)
27. Park SY, Lee JH, Shin HK, Kim CD, Lee WS, Rhim BY, Shin YW, and Hong KW (2008) Synergistic efficacy of concurrent treatment with cilostazol and probucol on the suppression of reactive oxygen species and inflammatory markers in cultured human coronary artery endothelial cells. Korean J Physiol Pharmacol 12:165-170.
28. Ross R (1999) Atherosclerosis - an inflammatory disease. N Engl J Med 340:115-126.
29. Sacco RL, Benson RT, Kargman DE, Boden-Albala B, Tuck C, Lin IF, Cheng JF, Paik MC, Shea S, and Berglund L (2001) High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA 285:2729-2735. (Pubitemid 32525369)
30. Sekiya M, Funada J, Watanabe K, Miyagawa M, and Akutsu H (1998) Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis. Am J Cardiol 82:144-147. (Pubitemid 28337722)
31. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, et al. (2010) Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 9:959-968.
32. Tanizaki Y, Kiyohara Y, Kato I, Iwamoto H, Nakayama K, Shinohara N, Arima H, Tanaka K, Ibayashi S, and Fujishima M (2000) Incidence and risk factors for subtypes of cerebral infarction in a general population: the Hisayama study. Stroke 31:2616-2622.
33. Tanne D, Koren-Morag N, Graff E, and Goldbourt U (2001) Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) Registry: high triglycerides constitute an independent risk factor. Circulation 104:2892-2897. (Pubitemid 33139099)
34. Tirschwell DL, Smith NL, Heckbert SR, Lemaitre RN, Longstreth WT Jr, and Psaty BM (2004) Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology 63:1868-1875. (Pubitemid 39532383)
35. Vaughan CJ, Delanty N, and Basson CT (2001) Statin therapy and stroke prevention. Curr Opin Cardiol 16:219-224. (Pubitemid 32751887)
36. White HD, Simes RJ, Anderson NE, Hankey GJ, Watson JD, Hunt D, Colquhoun DM, Glasziou P, MacMahon S, Kirby AC, et al. (2000) Pravastatin therapy and the risk of stroke. N Engl J Med 343:317-326. (Pubitemid 30616697)
37. Yamashita S, Hbujo H, Arai H, Harada-Shiba M, Matsui S, Fukushima M, Saito Y, Kita T, and Matsuzawa Y (2008) Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb 15:292-303.
38. Ye YL, Shi WZ, Zhang WP, Wang ML, Zhou Y, Fang SH, Liu LY, Zhang Q, Yu YP, and Wei EQ (2007) Cilostazol, a phosphodiesterase 3 inhibitor, protects mice against acute and late ischemic brain injuries. Eur J Pharmacol 557:23-31. (Pubitemid 46135554)
39. Yoshikawa T, Mitani K, Kotosai K, Nozako M, Miyakoda G, and Yabuuchi Y (2008) Antiatherogenic effects of cilostazol and probucol alone, and in combination in low density lipoprotein receptor-deficient mice fed with a high fat diet. Horm Metab Res 40:473-478.
40. Zhang X, Li Z, Liu D, Xu X, Shen W, and Mei Z (2009) Effects of probucol on hepatic tumor necrosis factor-alpha, interleukin-6 and adiponectin receptor-2 expression in diabetic rats. J Gastroenterol Hepatol 24:1058-1063.